Entia Biosciences (OTCMKTS:ERGO) is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of neurodegenerative disorders. The company’s research efforts center on novel molecular targets implicated in Alzheimer’s disease, Parkinson’s disease and other age-related neurological conditions. Utilizing a proprietary platform that integrates advanced RNA modulation with targeted delivery technologies, Entia Biosciences aims to address underlying disease mechanisms rather than only managing symptoms.
Since its founding in 2018 as a spin-out from leading academic laboratories in Cambridge, Massachusetts, Entia Biosciences has built a diversified pipeline of product candidates. Its lead program, EBR-101, is designed to restore healthy protein expression in neuronal cells and is currently advancing through preclinical toxicology studies. Additional discovery projects leverage the company’s in-house high-throughput screening capabilities to identify small molecules that modulate key pathways in protein misfolding and aggregation.
Headquartered in Boston, Entia Biosciences maintains a state-of-the-art research and manufacturing facility in Massachusetts and collaborates with clinical research sites across North America and Europe. The company has entered strategic partnerships with academic institutions and contract research organizations to accelerate IND-enabling studies and establish a clinical supply chain capable of supporting global trials.
Under the leadership of CEO Dr. Margaret Liu, a molecular biologist with over 20 years of industry experience, and a management team drawn from top biotech and pharmaceutical firms, Entia Biosciences is preparing to initiate its first human studies. With an emphasis on translational science and regulatory engagement, the company plans to advance its most promising candidates into Phase 1 trials, targeting patient populations with high unmet medical need.
AI Generated. May Contain Errors.
